Dreampath Diagnostics veut industrialiser la pathologie et lève des fonds auprès de Summit Partners

Dreampath Diagnostics Expands Pathology Automation with Summit Partners Investment

Based in Strasbourg, Dreampath Diagnostics is advancing its development phase with a growth financing from the American fund Summit Partners . Though the transaction amount remains confidential, the investment aims to support Dreampath’s international expansion and broaden its product range.

Established in 2012, Dreampath addresses the logistical challenges in medical diagnostics, specifically in tissue sample management . As laboratories face increasing analysis volumes, stricter traceability requirements, and staff shortages, the company provides an integrated platform combining scanners, proprietary software, and consumables to automate the archiving and retrieval of pathological samples.

Integrated Platform Designed for Industrial Use

Dreampath's solution is based on a closed-loop system that manages the entire lifecycle of tissue samples in a laboratory. The platform ensures interoperability with existing software infrastructures while maintaining strict control over its technical standards. Dreampath has secured its technology with over 80 international patents .

Currently, more than 250 million samples are managed via the platform in 500 laboratories across nearly 40 countries , including public hospitals, cancer centers, industrial laboratories, and research institutes. The company reports an 83% reduction in archiving time in equipped facilities.

By ensuring rigorous digital traceability, Dreampath helps minimize handling errors and secures the diagnostic process while reducing the operational burden on laboratory teams.

Summit Partners Joins Capital and Governance

With this investment, Dreampath welcomes Summit Partners as its first institutional partner. The fund, active in the healthcare and technology sectors, brings expertise in scaling high-growth companies.

Summit Partners sees Dreampath as an opportunity to establish a leading industrial player in a segment of medical diagnostics that remains largely undigitized. Representatives Thomas Tarnowski and Jono Pagden from Summit Partners will join Dreampath’s board of directors as part of this operation.

Dreampath claims a compound annual growth rate exceeding 50% in recent years, driven by demand in the United States, Europe, and other strategic markets. Its business model is based on the combined sale of software, hardware, and high-value consumables, ensuring recurring revenue.

The company plans to expand its industrial footprint, increase production capacity, and continue structuring its network of hospital and industrial partners.

D’après FrenchWeb.